Guo Yongren's mind involuntarily came to the idea that he searched on the Internet to see the information by chance, the history of blood and tears in the development of Chinese traditional Chinese medicine, which is completely a tragedy, pitiful, pathetic, lamentable, hateful.

According to statistics in 2014, the global Chinese medicine market was about 100 billion in 2014, while China accounted for only 9%, which came from the statistics of a foreign company. There may be deviations, but not too much. At present, it is recognized in the industry that foreign companies such as South Korea, Japan, and the United States directly monopolize about 90% of the international market share of Chinese patent medicine.

According to statistics, in the overseas Chinese medicine market, China has only 0.3% of the patent rights, while Japan and South Korea account for more than 70% of the traditional Chinese medicine patents.

Japan's largest Kampo pharmaceutical company, Tsumura Pharmaceutical, has established more than 70 GAP medicinal material planting bases in China, while Tong Ren Tang, a traditional Chinese medicine company with the largest number of GAP bases in China, has only 8, and the gap in number is very large.

As of the end of May 2014, China has certified a total of 152 GAP planting bases for 66 varieties of Chinese herbal medicines, of which more than 70 GAP medicinal material planting bases are controlled by Japan-Tsumura Pharmaceutical, and I don't know how many of the remaining 80 or so GAP medicinal material planting bases are controlled by Japan or other countries.

GAP refers to the "Regulations on the Quality Management of the Production of Chinese Herbal Medicines", which stipulates that R&D, production and management are carried out in accordance with internationally recognized standards and specifications.

In addition to the export of medicinal materials produced by Japan's GAP medicinal material planting base to Japan, a large number of high-quality Chinese herbal medicine raw materials with no heavy metals, pesticides and vulcanization are also exported to Japan.

At the same time, Japanese pharmaceutical companies strictly control the quality of traditional Chinese medicine raw materials, and resolutely do not allow heavy metals, pesticides, or other unqualified Chinese medicinal materials to enter their production workshops.

How terrifying it is that a Japanese pharmaceutical company controls nearly half of China's GAP medicinal herb cultivation base.

Japan's strategy in traditional Chinese medicine is to make it clear that "the formula originates from China, the medicinal materials are taken from China, and when Chinese traditional Chinese medicine companies are still self-absorbed, close the door to the internationalization of Chinese traditional Chinese medicine, and maximize the share of the international traditional Chinese medicine market." “

Since Japanese pharmaceutical companies understand that the origin of traditional Chinese medicine is China, but Chinese traditional Chinese medicine does not have global competitiveness, Japanese pharmaceutical companies have preemptively registered some patents for famous Chinese traditional Chinese medicine prescriptions in the European and American markets. For example, Imperial Pharmaceutical Co., Ltd. of Japan has preemptively registered U.S. patents for over-the-top medicines such as Jiawei Xiaoyaosan, Angelica Peony Soup, Guizhi Poria Pills, and Ulcerative Colitis Treatment Drugs

Due to the existence of patents, European and American pharmaceutical companies with strong intellectual property rights cannot produce, and at the same time, Chinese pharmaceutical companies in the country of origin cannot produce.

This piece of information slowly appeared in Guo Yongren's mind, this can be said to be the pain in the hearts of all Chinese people, but since he came, then these must be taken back, the monopoly of traditional Chinese medicine, must belong to the umbrella, this point is not negotiable, Guo Yongren made up his mind in his heart.

"That's Naomi, I'm going to Tokyo tomorrow, let's go together" Guo Yongren said directly, Hosokawa Naomi didn't doubt him, nodded and agreed.

The next day, Guo Yongren took Guan Du and Wang Dajun and them, as well as Hosokawa Naomi returned to Tokyo together, and Nagoya handed over to Takahashi Shogo to be in charge, there were not many things, Takahashi Masago and they had no problem at all.

When he arrived in Tokyo, Guo Yongren separated from Hosokawa Naomi, Guo Yongren returned to the hotel and went directly to Guan Du, and asked Guan Du to touch the foundation of the Ono Chinese medicine company that had declared bankruptcy, and at the same time to understand what the current situation of Japanese Chinese medicine companies looks like, gave Guan Du a check, and asked Guan Du to do something.

It took hundreds of thousands of dollars to spend a week, and the detailed report was placed in front of Guo Yongren, Guo Yongren looked at it seriously, the life of Japanese traditional Chinese medicine companies in this year is not easy, it can be said that they are barely living, there are many companies that can't send new books, and there are many small businesses that go bankrupt, which is a good time to copy the bottom.

The information is written in great detail, these companies have their own unique products, Guo Yongren thought about it, called Guan Du over, and the two began to discuss in the room.

Hand the enterprise directory to Guan Du, "Draw a circle on this, all of them will be acquired" Guo Yongren said directly, he didn't consider anything else at all, and he would take it first, not to mention that the acquisition cost was not big now.

Guan Du looked at it, more than a dozen companies, all of them are pharmaceutical factories, the scale is not large, and the life of the enterprise is not very good, what is the acquisition of pharmaceutical companies, and it is also traditional Chinese medicine, now people take Western medicine when they are sick, the effect is fast, and it also treats diseases, there is no value, and Guo Yongren looked at him a little puzzled.

"Don't ask why, let's do it, take this, the sooner the better" Guo Yongren said directly, now he is in no mood to explain, and at the same time gave Guan Du a cash check of 500,000 US dollars as the activity fund, Guan Du nodded, Guo Yongren is the boss, and the boss has decided to do it himself.

I went out with the catalog, and began to investigate more detailed information for negotiation, and the sooner the boss, the better, then there must be enough information, and I entrusted several more famous private detectives to carry out the operation.

Guan Du is now going out early and returning late every day, Guo Yongren basically does not go out in the hotel, and there is no mobile phone yet, and it is very inconvenient to contact, so he does not go, and keeps in touch with Guan Du at any time.

It only took ten days for the first company to be completed, followed by almost one a day, and in less than a month, the companies on Guo Yongren's list were all acquired.

Immediately afterwards, Guo Yongren did not start to integrate, but immediately began to apply for patents for the formulas and names of traditional Chinese medicine products held by these companies, not afraid of spending money, a patent costs a lot of money, but this money must be spent, Guo Yongren doesn't care at all, Guan Du is tired like a donkey, and his eyes are full of deep resentment every day when he looks at Guo Yongren.

When all the patent material applications were submitted, Guo Yongren and Guan Du breathed a sigh of relief, especially Guo Yongren, in order to ensure the smooth implementation, specially spent money to hire a lobbying company, Japan was established in imitation of the United States, the price is not cheap, 800,000 US dollars, to ensure the smooth approval of the patent, Guo Yongren paid directly without saying a word and signed an agreement, let the Japanese lobbying company operate.

After these things were done, Guo Yongren began to integrate these more than a dozen traditional Chinese medicine companies, and began to take stock of all the assets, after the inventory, Guo Yongren smiled, this acquisition only cost more than 30 million US dollars, but when he saw the harvest, Guo Yongren felt that he was really lucky.

More than a dozen companies in Tokyo have eight ready-made buildings, the highest 16 floors, the lowest 4 floors, and then there are suburban factories and other assets, you must know that it is only 81 years now, and Tokyo is one of the cities with the highest housing prices in the world, and it is unimaginable how much these will appreciate in the future.

Another thing that makes Guo Yongren feel very pleased is that these more than a dozen companies, basically all of them are family-managed, after Guo Yongren's acquisition, many high-level executives have consciously left, these people do not have much ability, but occupy a high position, now it is good, a lot of positions have been vacated.

Guo Yongren started another round of intense interviews, and at the same time looked at their resumes, and it took a whole week to determine the candidates for the umbrella medical department, and there were many people.

The 16-storey building, which was located in a good location, was officially renamed the Umbrella Medical Building, and a new renovation began, which would be the headquarters of a Japanese pharmaceutical company.

Eisuke Ita: Appointed as the General Manager of Umbrella Pharmaceuticals (Japan Branch).

Hideyuki Tanaka: Appointed as Deputy General Manager of Umbrella Pharmaceuticals (Japan Division).

Kamiji Ida: Appointed as Deputy General Manager of Umbrella Pharmaceuticals (Japan Division).

Kaede Hasegawa: Appointed as the Manager of the Administration Department of Umbrella Pharmaceuticals (Japan Branch).

Bao Ke Shou: Appointed as the Manager of the Herbal Medicine Purchasing Department of Umbrella Pharmaceuticals (Japan Branch).

Yuji Ohno: Appointed as Deputy Manager of the Herbal Medicine Purchasing Department of Umbrella Pharmaceuticals (Japan Branch).

Yan Hui Mitsui: Appointed as Deputy Manager of the Herbal Medicine Purchasing Department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Professor Tomoko Saihira: Appointed as the head of the scientific research department of Umbrella Pharmaceuticals (Japan Branch).

Professor Mu Chenhachi: Appointed as the Minister of Welfare of the Scientific Research Department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Professor Hidenaka Sato: Appointed as the head of the research department of Umbrella Pharmaceuticals (Japan Branch).

Shuichi Minamino: Appointed as General Manager of Sales of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Miyazaki Tatsui: Appointed as Deputy Director of Sales Department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Kiyoshi Kobayashi: Appointed as Deputy Director of Sales Department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Nakahiko: Appointed as the head of the quality control department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Yuehua Blade: Appointed as the deputy director of the quality control department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Takuya Hanazawa: Appointed as Deputy Director of Quality Control Department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Ryuichi Horibe: Appointed as the deputy director of the quality control department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

Katsuhei Yamaguchi: Appointed as Marketing Manager of Umbrella Pharmaceuticals (Japan Division).

Kazuhiko Inoue: Appointed as Deputy Manager of the Marketing Department of Umbrella Pharmaceuticals (Japan Division).

Takashi Changden: Appointed as Deputy Manager of the Marketing Department of Umbrella Pharmaceutical Co., Ltd. (Japan Branch).

It is not difficult to see from this appointment that Guo Yongren has worked the quality control of products, and other departments are basically one and two pairs, but the quality control department is a three-member configuration, and product quality is the foundation of the survival of the enterprise.

At the same time, Guo Yongren transferred two treasurers from Hong Kong to set up the finance department of the umbrella pharmaceutical company, with the international accounting firm PricewaterhouseCoopers as the company's contracted audit agency, and the Japanese branch of Fillson Law Firm in the United States as the legal audit agency of the pharmaceutical company.